AOAnna Onisiforou

Anna Onisiforou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Onisiforou has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The many faces of Epstein-Barr virus: sex-biased disease outcomes in autoimmune diseases, cancer, and neurodegeneration

    by Anna Onisiforou, Polymnia Georgiou, Panos Zanos

    Epstein–Barr virus (EBV) infects over 95% of people worldwide. Although primary infection is usually asymptomatic, it is linked to a wide range of diseases, including cancers, autoimmune diseases, and neurodegenerative diseases. This review looks at the various clinical outcomes associated with EBV infection. It highlights the established role of EBV in cancer development and its strong associations with autoimmune diseases. It also discusses new evidence linking EBV to neurodegenerative diseases, specifically Alzheimer’s disease. A key focus of this review is how biological sex influences EBV-associated disease outcomes. We explore how sex chromosomes, X-chromosome inactivation, sex hormones, and sex-specific immune responses explain the significant differences between women and men in their susceptibility to autoimmune diseases, neurodegeneration, and EBV-related cancers. By bringing together evidence from these disease categories, this review emphasizes biological sex as an important yet often overlooked factor in the differences seen in EBV-associated diseases and points out critical areas that need more detailed research.

  • Open Access

    AI-bioinformatics synergy for precision medicine in brain diseases: integrating radiomics and multi-omics data

    by Bekir Altas, Polymnia Georgiou, Anna Onisiforou

    The convergence of artificial intelligence (AI) and bioinformatics is reshaping the landscape of precision medicine in brain diseases, particularly in neurological diseases and brain tumors. Despite advances in both fields, the combined application of radiomics and multi-omics fusion remains underutilized, even though integrative frameworks are essential for addressing the complexity and heterogeneity of imaging and molecular data. This review examines how integrative AI-bioinformatics frameworks enable the fusion of radiomics with genomics, transcriptomics, proteomics, and other omics modalities to more comprehensively model disease complexity. Leveraging deep learning, graph neural networks, and advanced representation learning, these multimodal systems facilitate biomarker discovery, patient stratification, and personalized treatment strategies. We critically evaluate key challenges including data heterogeneity, limited interpretability, and barriers to clinical validation, and highlight emerging solutions aimed at enhancing reproducibility and translational readiness. Case studies in gliomas, Alzheimer’s disease, and multiple sclerosis illustrate the clinical utility of unified imaging-omics architectures. Ultimately, this review positions radiomics and multi-omics integration as a foundational approach for the next generation of precision medicine in brain diseases by bridging the gap between computational innovation and clinical application.

  • Open Access

    The Immunosuppression Paradox in Multiple Sclerosis: Are We Fueling the Fire by Suppressing Immunity in an Epstein–Barr Virus–Linked Disease?

    by Anna Onisiforou

    Recent studies strongly implicate Epstein–Barr virus (EBV) as a necessary trigger for multiple sclerosis (MS). Longitudinal data show that EBV seroconversion precedes MS onset, while mechanistic studies identify molecular mimicry between EBV antigens and central nervous system proteins. Yet, MS treatments remain largely immunosuppressive, potentially impairing antiviral surveillance required to control EBV latency. Therapies that deplete T cells or impair lymphocyte trafficking have been linked to EBV-driven lymphoproliferative complications, potentially leading to EBV reactivation and exacerbation of MS. In contrast, B-cell–depleting therapies may reduce EBV reservoirs by targeting infected memory B cells and thus be more suited to treating EBV-associated MS. In this Review, we examine the paradox of treating an EBV-associated disease with immunosuppression, highlight data suggesting EBV reactivation under certain MS therapies, and propose that future MS management may require integration of EBV-targeted strategies, including vaccines and virus-directed immunotherapies, to address the underlying viral etiology.


  • Open Access

    Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer’s disease via dual actions

    by Andrea Georgiou, Panos Zanos, Anna Onisiforou

    Background Alzheimer’s disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping biological mechanisms, and diabetes increases the risk of developing AD. Treatments that modify the course of diabetes, such as metformin and semaglutide, have been proposed to protect the brain, but their effectiveness in preventing AD remains uncertain. This study aimed to systematically compare the potential of diabetes therapies to reduce the risk of AD. Methods We developed an integrative framework combining comparative network pharmacology to evaluate 39 diabetes therapies in relation to AD. The analysis examined how each treatment influenced shared molecular pathways between the two conditions and measured their comparative impact score and validated key findings using gene expression data. Results Here we show that metformin is the most promising therapy for protection against AD, while semaglutide ranks among the least effective, based on comparative analysis within the DM2-AD pathway-pathway comorbidity network. Metformin’s effects are mediated through AMPK, insulin, and adipocytokine signaling, that influence key Alzheimer’s-related processes. In contrast, semaglutide, despite its growing clinical prominence as a weight loss therapy, exhibits minimal engagement with core neurodegenerative pathways within the DM2-AD comorbidity network. Certain combination therapies, such as insulin glargine with lixisenatide and insulin degludec with liraglutide, display effects comparable to metformin. Conclusions These findings reveal that diabetes therapies differ in their ability to protect against AD. Metformin shows the strongest potential, supporting its prioritization for targeted studies in people with diabetes who are at high risk of AD, and highlighting the importance of precision medicine in future prevention trials.


  • Open Access

    From Heatwaves to Brainwaves: Climate-Driven Microplastics Promote Epstein–Barr Virus Reactivation and Female-Biased Risk for Alzheimer’s Disease and Multiple Sclerosis

    by Polymnia Georgiou, Bekir Altas, Marios Onisiforou, Panos Zanos, Anna Onisiforou

    Background Climate change accelerates plastic degradation, increasing human exposure to microplastics and their associated endocrine-disrupting additives, thereby reshaping the chemical exposome. Many of these compounds, including bisphenols and phthalates, act as xenoestrogens capable of perturbing hormonal, immune, and oxidative stress pathways within the internal biological exposome. Persistent viral infections such as Epstein–Barr virus (EBV), which dynamically interact with immune and redox regulation, further shape the biological exposome. We hypothesized that climate-associated microplastic compounds may converge with EBV-related molecular networks within the exposome that are implicated in Alzheimer’s disease (AD) and multiple sclerosis (MS). Methods We developed a computational exposome modelling framework integrating network toxicology and systems bioinformatics to map known and predicted human targets of microplastic-derived compounds with EBV–host protein–protein interactions and AD- and MS-associated proteins. Integrated interaction networks were constructed, and pathway enrichment analyses were performed to identify molecular points of convergence across environmental, viral, and disease-associated networks. Results Microplastic-responsive targets were enriched in immune, oxidative stress, and endocrine signalling pathways within both AD and MS networks and overlapped extensively with viral infection–associated pathways, including EBV. EBV interfaced with a greater number of AD-associated proteins than MS-associated proteins, whereas immune-related pathways predominated in MS. A conserved set of 20 EBV–microplastic “dual-hit” host proteins was identified across both diseases. In AD, the dual-hit neighbourhood was enriched for neuronal, metabolic, and hormone-responsive pathways, including neurotrophin signalling, dopaminergic synapse, estrogen signalling, apoptosis, and cellular senescence. In MS, enrichment was dominated by innate and adaptive immune pathways, including Toll-like receptor, IL-17, TNF, and JAK–STAT signalling. Estrogen signalling emerged as an AD-specific enriched pathway, while progesterone-mediated oocyte maturation was enriched in both diseases. Conclusions These findings provide systems-level, hypothesis-generating evidence that climate-associated microplastic exposure may intersect with endocrine and EBV-related host pathways relevant to neurodegenerative and autoimmune disease vulnerability. Although experimental validation is required, this exposome-based framework highlights molecular convergence points through which environmental and viral factors may jointly modulate disease-relevant biological networks, with potential implications for sex-related differences in susceptibility.

  • Open Access

    VirTarget: Virus-Informed Pharmacogenomics Framework Identifies Immunotherapies That Mitigate Epstein–Barr Virus–Driven Dysregulation in Multiple Sclerosis

    by Bekir Altas, Polymnia Georgiou, Marios Onisiforou, Panos Zanos, Anna Onisiforou

    Background: Epstein–Barr virus (EBV) is increasingly recognized as a central driver of multiple sclerosis (MS), yet current immunotherapies are selected without regard to their effects on EBV or EBV–MS genetic interactions. To address this gap, we developed VirTarget , the first virus-informed pharmacogenomics network framework that systematically evaluates approved MS immunotherapies with respect to EBV-driven pathogenesis and host genetic susceptibility risk. Methods: VirTarget integrates three complementary layers: (1) EBV–host interactomics, mapping viral–host protein– protein interactions within MS-relevant pathways; (2) host genetic susceptibility, linking MS-associated variants to EBV-targeted, therapy-modulated networks; and (3) transcriptomics directionality analysis, contrasting drug signatures with the convergent MS–EBV transcriptomic signature to classify therapies as reinforcers or reversers. Results: Network analysis revealed substantial heterogeneity among therapies. Dimethyl fumarate showed the strongest and broadest engagement with the MS–EBV network, followed by natalizumab and interferons, while anti-CD20 antibodies and S1P modulators exerted the weakest effects. Genetic mapping highlighted convergence on key risk genes ( HLA-DRB1, IL7R, IL2RA, CD40, TYR ) directly targeted by EBV proteins within therapy-modulated pathways. Transcriptomic profiling stratified therapies into reinforcers (e.g., dimethyl fumarate, fingolimod, dexamethasone, interferon-β1b) and reversers (e.g., prednisolone, cladribine, interferon-β1a, rituximab), reflecting opposing influences on the MS∩EBV signature. Notably, multiple therapies reversed EBV-driven dysregulation of cytokine and innate immune pathways, suggesting their benefits extend in counteracting viral-mediated modulation of immune processes. Conclusion: VirTarget provides the first systems-level, virus-informed comparative map of how MS immunotherapies engage with the MS–EBV network, intersect with MS genetic susceptibility risk, and modulate both MS- and EBV-related transcriptomic signatures. By revealing drug-specific patterns of viral pathway engagement and genetic convergence, this framework establishes a foundation for precision treatment strategies in MS, where therapeutic selection is informed by viral serostatus, host genetics, and system-level transcriptomic responses.


  • Open Access

    VirTrack: A Framework for Inferring Viral Influence on Disease-Associated Transcriptomes — Clinical Type-Specific Epstein–Barr Virus Pathogenesis in Multiple Sclerosis

    by Anna Onisiforou

    Background: Epstein–Barr virus (EBV) is strongly implicated in Multiple Sclerosis (MS), but how its influence varies across MS clinical types remains unclear. Methods: We developed VirTrack , a computational framework that integrates experimentally validated EBV–host protein–protein interactions (PPIs) with clinical type–specific peripheral blood transcriptomes from Clinically Isolated Syndrome (CIS), Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS), and Primary Progressive MS (PPMS) (GSE136411). VirTrack (i) anchors viral interactions in differentially expressed genes (DEGs), (ii) ranks EBV targeting of DEGs and host hubs, and (iii) applies machine learning– based clustering to identify clinical type–specific functional pathways influenced by EBV. Results: EBV engagement was clinical type–dependent. In early MS (CIS and RRMS), EBV targeted approximately 13–18% of dysregulated genes, enriching for B-cell–related processes, Toll-like receptor signaling, and infection-like inflammatory pathways, while suppressing antiviral and NF-κB responses. Progressive clinical types exhibited fewer viral connections but distinct mechanistic shifts: SPMS was characterized by suppression of vascular and cardiac repair–associated pathways, whereas PPMS was dominated by upregulation of vacuolar and lysosomal remodeling processes. Hub analyses revealed a stable core of influential EBV proteins, EBNA-LP (consistently top-ranked), BZLF1, BVLF1, LMP2, and BDLF4, while BNLF2A showed broad but less hub-focused targeting and LMP1 ranked low across types. Conclusion: EBV shapes MS through dynamic, clinical type–specific perturbations, driving strong immunomodulation in early disease and selective cellular remodeling during progressive types. VirTrack identifies key viral proteins and host pathways for stage-tailored therapeutic targeting, supporting early EBV-directed interventions and revealing potential links to vascular comorbidity in progressive MS types. More broadly, VirTrack offers a generalizable, systems-level framework for elucidating viral contributions across complex human diseases.


  • Open Access

    Selective transcriptomic recovery by ( 2R,6R )-hydroxynorketamine in opioid-abstinent mice: Machine learning identifies predictive biomarkers

    by Anna Onisiforou, Morfeas Koumas, Andria Michael, Panos Zanos

    Background: Opioid abstinence induces persistent emotional disturbances and widespread neuroplastic changes, in areas of the brain including the hippocampus. Although ketamine and its metabolite ( 2R,6R )-hydroxynorketamine (HNK) show potential in reversing opioid abstinence-related deficits in rodents, the molecular mechanisms underlying their efficacy remain poorly understood. Methods: Male C57BL/6J mice underwent a 3-week opioid abstinence paradigm, followed by a single (2R,6R)-HNK (10 mg/kg, i.p.) or saline injection on day 28. Sucrose and social preference tests were used to assess behavioral deficits. We conducted RNA sequencing of ventral hippocampal tissue from these mice, followed by differential gene expression and functional enrichment analyses. Additionally, Random Forest machine was applied to identify predictive differentially expressed genes (DEGs) associated with ( 2R,6R )-HNK treatment response. Results: Transcriptomic analysis identified 206 DEGs in morphine-abstinent mice without treatment compared to opioid-naïve controls (MOR-SAL vs. SAL-SAL), implicating altered immune signaling, synaptic function, and structural plasticity. Comparison of opioid-abstinent mice treated with ( 2R,6R )-HNK to opioid-naive controls (MOR-HNK vs. SAL-SAL) revealed 186 residual DEGs, enriched for Th17-mediated immune and fear regulation pathways, suggesting a persistent intermediate molecular phenotype despite normalized behavioural scores. DEGs overlap analysis between MOR-HNK vs . MOR-SAL and MOR-SAL vs . SAL-SAL indicated that ( 2R,6R )-HNK treatment reversed 55 DEGs in opioid-abstinent mice, including Transthyretin ( Ttr ) and T-cell surface glycoprotein ( Cd5 ) expression levels. Machine learning identified interleukin 1 receptor accessory protein-like 1 ( Il1rapl1) and cytotoxic T lymphocyte-associated protein 2 beta ( Ctla2b) as top predictors of ( 2R,6R )-HNK’s treatment response. Notably, while (2R,6R)-HNK induces transcriptional changes in opioid-naive mice (SAL-HNK), it does not affect behavior compared to untreated controls (SAL-SAL). In contrast, its therapeutic effects are evident in morphine-abstinent mice (MOR-HNK), highlighting its context-dependent efficacy. Conclusion: (2R,6R)-HNK promotes both transcriptional and behavioral recovery in opioid-abstinent mice, reversing key gene expression changes. However, persistent dysregulation of neuroimmune and emotion-related pathways suggests an intermediate molecular state, reflecting ongoing recovery.

  • Open Access

    (2R,6R)‐hydroxynorketamine prevents opioid abstinence‐related negative affect and stress‐induced reinstatement in mice

    by Andria Michael, Anna Onisiforou, Polymnia Georgiou, Morfeas Koumas, Chris Powels, Elmar Mammadov, Andrea N. Georgiou, Panos Zanos

    Background and Purpose: Opioid use disorder (OUD) is a pressing public health concern marked by frequent relapse during periods of abstinence, perpetuated by negative affective states. Classical antidepressants or the currently prescribed opioid pharmacotherapies have limited efficacy to reverse the negative affect or prevent relapse.Experimental Approach: Using mouse models, we investigated the effects of ketamine's metabolite (2R,6R)‐hydroxynorketamine (HNK) on reversing conditioning to sub‐effective doses of morphine in stress‐susceptible mice, preventing conditioned‐place aversion and alleviating acute somatic abstinence symptoms in opioid‐dependent mice. Additionally, we evaluated its effects on anhedonia, anxiety‐like behaviours and cognitive impairment during protracted opioid abstinence, while mechanistic studies examined cortical EEG oscillations and synaptic plasticity markers.Key Results: (2R,6R)‐HNK reversed conditioning to sub‐effective doses of morphine in stress‐susceptible mice and prevented conditioned‐place aversion and acute somatic abstinence symptoms in opioid‐dependent mice. In addition, (2R,6R)‐HNK reversed anhedonia, anxiety‐like behaviours and cognitive impairment emerging during protracted opioid abstinence plausibly via a restoration of impaired cortical high‐frequency EEG oscillations, through a GluN2A‐NMDA receptor‐dependent mechanism. Notably, (2R,6R)‐HNK facilitated the extinction of opioid conditioning, prevented stress‐induced reinstatement of opioid‐seeking behaviours and reduced the propensity for enhanced morphine self‐consumption in mice previously exposed to opioids.Conclusions and Implications: These findings emphasize the therapeutic potential of (2R,6R)‐HNK, which is currently in Phase II clinical trials, in addressing stress‐related opioid responses. Reducing the time and cost required for development of new medications for the treatment of OUDs via drug repurposing is critical due to the opioid crisis we currently face.


  • Open Access

    Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus Triggers

    by Andrea Georgiou, Panos Zanos, Anna Onisiforou

    Alzheimer’s disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping pathological mechanisms, with DM2 increasing AD risk. Disease-modifying therapies (DMTs) for DM2, including Metformin and Semaglutide, have been explored for neuroprotection, yet their efficacy in AD remains unclear. Here, we introduce a novel integrative framework combining comparative network pharmacology, Mendelian Randomization (MR), and transcriptomic validation to systematically assess the therapeutic impact of 39 DM2 DMTs in preventing AD in DM2. Metformin emerged as the top-ranked therapy, whereas Semaglutide ranked among the least effective based on comparative analysis within the DM2-AD pathway-pathway comorbidity network. Notably, a two-sample MR analysis finds no evidence supporting a genetic liability to either drug being associated with AD risk, suggesting that their benefits may arise through non-direct mechanisms or that their relationship could be confounded by third factors. Metformin’s neuroprotective impact is mediated through AMPK, insulin, and adipocytokine signaling, which regulate key AD-related processes. Additionally, Metformin may indirectly affect herpesviruses, emerging environmental contributors to AD, potentially enhancing its neuroprotective effects. In contrast, Semaglutide, despite its growing clinical prominence as a weight loss therapy, exhibits minimal engagement with core neurodegenerative pathways within the DM2-AD comorbidity network, highlighting variability in neuroprotective potential across DM2 DMTs. Furthermore, specific dual-action therapies (e.g., Insulin Glargine and Lixisenatide, Insulin Degludec and Liraglutide) exhibit efficacy comparable to Metformin, reinforcing the need for a precision medicine approach. These findings challenge the assumption that all DM2 DMTs confer equal neuroprotection, revealing significant differences in their impact on AD-related pathways. While some show strong potential for AD prevention, others appear far less effective. Metformin’s effects depend on genotype, disease state, and environmental factors, underscoring the need to re-evaluate DM2 DMTs for AD prevention in population-specific clinical trials. Metformin stands out as a strong candidate for targeted investigations in DM2 patients at high risk of AD.